Lin Rui Li

US Patent:

6569878, May 27, 2003

Filed:

Oct 27, 1998

Appl. No.:

09/179744

Inventors:

Wesley K. M. Chong - Encinitas CA
Shao Song Chu - Encinitas CA
Lin Li - San Diego CA
Rohit K. Duvadie - San Diego CA
Yi Yang - San Diego CA
Wei Xiao - San Diego CA

Assignee:

Agouron Pharmaceuticals Inc. - San Diego CA

International Classification:

A61K 31425

US Classification:

514370, 514218, 514255, 514326, 544360, 544367, 546208, 546209, 548191, 548194, 540575

Abstract:

Pharmaceutical compositions containing effective amounts of CDK-inhibiting diaminothiazole compounds of the following formula (where R and R are as defined in the specification) or their salts, or prodrugs or active metabolites of such compounds or salts, are useful for treating disorders and diseases such as cancer: In preferred embodiments, R and R are independently unsubstituted or substituted carbocyclic or heterocyclic aryl ring structures. Compounds where R is ortho-substituted aryl are especially potent inhibitors of CDKs such as CDK4.

US Patent:

6720346, Apr 13, 2004

Filed:

Jul 5, 2002

Appl. No.:

10/190219

Inventors:

Shao Song Chu - Carlsbad CA
Larry Andrew Alegria - San Diego CA
Ted Michael Bleckman - La Jolla CA
Wesley Kwan Mung Chong - Encinitas CA
Rohit K. Duvadie - San Diego CA
Lin Li - San Diego CA
Siegfried Heinz Reich - Solana Beach CA
Michael B. Wallace - San Diego CA
Yi Yang - San Diego CA

Assignee:

Agouron Pharmaceuticals, Inc. - San Diego CA

International Classification:

A61K 31425

US Classification:

514370, 548191, 548194

Abstract:

Aminothiazole compounds with mono-/di-substituted benzamide are represented by the Formula (I), and their pharmaceutically acceptable salts, pharmaceutically acceptable prodrugs, pharmaceutically active metabolites, and pharmaceutically acceptable salts of said metabolites are described. These agents modulate and/or inhibit the cell proliferation and activity of protein kinases and are useful as pharmaceuticals for treating malignancies and other disorders.

US Patent:

6870581, Mar 22, 2005

Filed:

Oct 30, 2001

Appl. No.:

10/003947

Inventors:

Lin Li - Vancouver WA, US
Jeffrey Brian Sampsell - Vancouver WA, US
Jagtar Singh Saroya - Washougal WA, US
George Stuart Vernon - Milwaukie OR, US

Assignee:

Sharp Laboratories of America, Inc. - Camas WA

International Classification:

H04N005/74

US Classification:

348756, 353 31, 349 9, 359216

Abstract:

A projection display system. The projection system includes a light source, illumination optics that are capable of splitting the light from the source into individual color bands, and folding mirrors. The folding mirrors operate to direct the color bands to a reflective element that has a contoured surface. The contoured surface of the reflective element causes the light to form into scanning rasters that are recombined and sent to a spatial light modulator. The spatial light modulator is typically made up of a panel of individually addressable elements. If the spatial light modulator requires polarized light, a polarizing beam splitter and quarter-wave plate are included as part of the illumination optics.

US Patent:

7799117, Sep 21, 2010

Filed:

Sep 27, 2006

Appl. No.:

11/535630

Inventors:

Lin Li - Albany CA, US
Mark E. Schott - Palatine IL, US
Andrew S. Zarchy - Kildeer IL, US
Bradley P. Russell - Wheaton IL, US

Assignee:

UOP LLC - Des Plaines IL

International Classification:

B01D 53/02

US Classification:

95 96, 95 99, 95105, 95106, 95114, 96126, 96130, 96146

Abstract:

A thermal sink is used to recover heat from a product gas leaving an adsorption vessel in a thermal swing adsorption process. Heat that is recovered from the product gas is used to heat a regeneration gas during the subsequent regeneration of the adsorbent material within the adsorption vessel. The step in which the regenerated bed of adsorbent material is cooled prior to returning to adsorption mode is eliminated.

US Patent:

8197670, Jun 12, 2012

Filed:

Feb 23, 2010

Appl. No.:

12/711124

Inventors:

Lin Li - Richmond CA, US
Hua-Min Huang - Hercules CA, US
Zunqing He - San Rafael CA, US

Assignee:

Chevron U.S.A. Inc. - San Ramon CA

International Classification:

C10G 17/00

US Classification:

208208R, 208251 R

Abstract:

A process is disclosed using a dispersion of supercritical fluid and oil to upgrade a hydrocarbon feedstock such as a heavy oil into an upgraded hydrocarbon product or synthetic crude with highly desirable properties such as low sulfur content, low metals content, lower density (higher API), lower viscosity, lower residuum content, etc. The process utilizes a capillary mixer to form the dispersion. The process does not require external supply of hydrogen nor does it use externally supplied catalysts.

US Patent:

8389782, Mar 5, 2013

Filed:

Aug 31, 2010

Appl. No.:

12/873113

Inventors:

Zhen Zhou - Emeryville CA, US
Lin Li - Albany CA, US
Shabbir Husain - San Pablo CA, US

Assignee:

Chevron U.S.A. Inc. - San Ramon CA

International Classification:

C07C 1/207

US Classification:

585240, 585 14, 585242, 585640, 585733, 44385, 44386

Abstract:

A process useful for treating biologically derived oils in the production of biofuels is described. A biologically derived oil feed is deoxygenated by contacting the feed with a metal titanate catalyst comprising a metal titanate having an MTiOperovskite structure wherein M is a metal having a valence of 2+. The process does not require the addition of hydrogen.

US Patent:

20030220326, Nov 27, 2003

Filed:

Mar 13, 2003

Appl. No.:

10/388851

Inventors:

Wesley Chong - Encinitas CA, US
Shao Chu - Encinitas CA, US
Lin Li - San Diego CA, US
Rohit Duvadie - San Diego CA, US
Yi Yang - San Diego CA, US
Wei Xiao - San Diego CA, US

International Classification:

A61K031/551
A61K031/541
A61K031/496
C07D417/14
C07D417/02

US Classification:

514/218000, 514/227800, 514/253100, 514/254020, 544/360000, 540/575000, 544/369000, 544/060000

Abstract:

Pharmaceutical compositions containing effective amounts of CDK-inhibiting diaminothiazole compounds of the following formula (where Rand Rare as defined in the specification) or their salts, or prodrugs or active metabolites of such compounds or salts, are useful for treating disorders and diseases such as cancer: In preferred embodiments, Rand Rare independently unsubstituted or substituted carbocyclic or heterocyclic aryl ring structures. Compounds where Ris ortho-substituted aryl are especially potent inhibitors of CDKs such as CDK4.

US Patent:

20040176431, Sep 9, 2004

Filed:

Feb 11, 2004

Appl. No.:

10/776450

Inventors:

Wesley Chong - Encinitas CA, US
Shao Chu - Encinitas CA, US
Rohit Duvadie - San Diego CA, US
James Na - San Diego CA, US
Lana Schaffer - San Diego CA, US
Yi Yang - San Diego CA, US
Lin Li - San Diego CA, US

Assignee:

Pfizer, Inc.

International Classification:

A61K031/427
A61K031/426
C07D417/02

US Classification:

514/370000, 548/181000, 548/194000

Abstract:

Aminothiazole compounds substituted with sulfur-containing groups are represented by the Formula (I), and their pharmaceutically acceptable salts, prodrugs, active metabolites, and pharmaceutically acceptable salts of said metabolites are described. These agents modulate and/or inhibit the cell proliferation and activity of protein kinases and are useful as pharmaceuticals for treating malignancies and other disorders.